4.6 Article

B2M mutation paves the way for immune tolerance in pathogenesis of Epstein-Barr virus positive diffuse large B-cell lymphomas

Journal

JOURNAL OF CANCER
Volume 13, Issue 14, Pages 3598-3605

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/jca.75813

Keywords

Epstein-Barr virus; EBV plus DLBCL; Gene mutation; B2M; Immune tolerance

Categories

Funding

  1. Shanghai PujiangTalent Program of China
  2. [18PJD055]

Ask authors/readers for more resources

This study investigated the genetic pathogenesis and tumor microenvironment of EBV positive DLBCL in patients without immunodeficiency. The results showed that B2M mutations were significantly increased in these cases and were related to poor patient outcomes. B2M mutations disrupt the expression and functions of HLA, leading to decreased T lymphocyte infiltration in tumor tissues, thus reducing the recognition and elimination of EBV+ tumor cells by the host immune system.
This study focused genetic pathogenesis and tumor microenvironment of Epstein-Barr virus (EBV) positive diffuse large B-cell lymphomas (DLBCL) in patients without immunodeficiency. DNA samples from these cases were sequenced by next generation sequencing (NGS) using a selected gene panel. Results revealed that most gene mutations were not specific for EBV positive DLBCL. However, B2M (beta 2-microglobulin) mutations were significantly increased and HLA-I or HLA-II expression was decreased in these cases, which was related to patient's poor outcome. B2M mutations and deregulation of B2M expression were further confirmed by Sanger sequencing and immunohistochemistry. Reducing the infiltration of CD8+ T lymphocytes, related to decreased expression of HLA-I or HLA-II was found in these patients. These results suggest that the mutations of B2M could cause the disruption of the expression and functions of this important subunit of HLA, leading to decreased expression of HLA-I or HLA-II and subsequently to reduce T lymphocyte infiltration in tumor tissues. The consequence of this event lessens the recognition and elimination of EBV+ tumor cells by host immunity and paves the way for the host immune tolerance to EBV+ tumor cells by evading immune recognition and escaping the T lymphocyte killing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available